权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Adaptation of Cognitive Enhancement Therapy for persons at Psychosis High Risk

针对精神病高危人群的认知增强疗法的调整

基本信息

批准号：
8976169
负责人：
MATCHERI S. KESHAVAN
金额：
$ 26.1万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-12-01 至 2017-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8976169
关键词：
Address Adolescent Development Adult Antipsychotic Agents Attention Attenuated Caring Chronic Clinical Cognition Cognitive Therapy Cognitive remediation Communities Data Deterioration Development Dose Early Intervention Family Fatty Acids Focus Groups Goals Health Impaired cognition Impairment Individual Innovative Therapy Intervention Intervention Studies Learning Manuals Memory Meta-Analysis Neuronal Plasticity Omega-3 Fatty Acids Participant Persons Phase Population Prevention approach Procedures Psychopathology Psychotic Disorders Public Health Randomized Controlled Trials Recruitment Activity Research Schizophrenia Speed Supervision Symptoms Techniques Testing Training adverse outcome base clinical practice cognitive disability cognitive enhancement executive function experience functional disability functional outcomes gray matter high risk improved indicated prevention novel open label psychiatric symptom psychosocial social social cognition social situation trait treatment adherence treatment response

项目摘要

DESCRIPTION (provided by applicant): Persons at clinical high risk (CHR) state for psychosis are characterized by attenuated or transient psychotic episodes, trait vulnerability and functional deficits. If untreated, a significant proportion of CHR individuals have adverse outcomes, including conversion to psychosis, other psychopathology and functional deterioration. Despite enhanced CHR research focus over the past decade there are few established prevention approaches. This proposal seeks to develop, evaluate feasibility, acceptability and obtain preliminary data on efficacy of a novel manualized approach for cognitive enhancement, the Cognition for Learning and for Understanding Everyday Social Situations (CLUES) in individuals at clinical high risk (CHR) for psychosis. This approach is based on the principles and approaches of cognitive enhancement therapy (CET), shown by this research group to have efficacy, generalizability to functional outcome, durability and possible neuroprotective effects. In Phase 1 (0-6 months) we will adapt CET techniques to the symptomatic, functional, and developmental features of CHR, train staff and develop assessment procedures and a manual for the CLUES intervention with the help of a focus group and input from an advisory group of experts. In phase 2, using a feasibility trial (n=8) we will assess acceptability, tolerability, treatment adherence, treatment fidelity, and obtain preliminary evidence of target engagement (i.e. change in cognition and social cognition). .In Phase 3 (19-36 months) we will conduct a randomized control trial to generate pilot efficacy, generalization to functional outcome, durability and tolerability data on CLUES in CHR individuals (n=30). These data will serve as a prerequisite to a later, larger-scale intervention study of CLUES in the CHR population.